DUBLIN--(BUSINESS WIRE)--The "Global Bicycle Toxin Conjugates Clinical Trials & Market Opportunity Insight 2024" report has been added to ResearchAndMarkets.com's offering. In the inexhaustible search ...

Bicycle Therapeutics has filed to raise up to $86 million in a Nasdaq IPO. The British biotech wants the money to prepare for phase 2 and 3 clinical trials of its lead anticancer candidate, BT1718.

Join us for an exhilarating adventure with Samuel, a professional cyclist and the Stlow-Vac National Champion, as he ...

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary ...

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary ...

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary ...

Trek has a broad range of road bike offerings for road and all-road performance. Add to that a time trial and triathlon bike, plus a broad range of cyclocross and gravel models with the electric ...